Health Care · Pharmaceutical Preparations

OMER OMEROS CORP SEC Filings & Insider Trading Activity 2026

company
CIK 1285819120 filings
Russell 2000

OMER at a glance

OMEROS CORP (OMER, SEC CIK 1285819) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as October 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding OMEROS CORP (OMER) shares worth $324.9 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Borges David J. on September 23, 2026 of 10,000 shares at $20.95 per share.
  • In the last 90 days, OMER insiders reported 0 open-market purchases ($0) and 8 open-market sales ($1.6M) on Form 4, a net sale of $1.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 8 sells
Net −$1.6M
13F holders
27 funds
$324.9M · +2 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $35.9M vs $0 YoY, following YARTEMLEA launch in January 2026
  • Gross margin approximately 100% in Q3, reflecting low-cost pre-approval inventory
  • YARTEMLEA: $35.9M net sales, 109 ordering accounts, up 49% from June 30
  • Cash, equivalents and short-term investments $95.3M; operating cash flow $13.3M
  • Q4 R&D and SG&A expected higher; EU authorization not expected after negative CHMP opinion

Risk Factors

  • New market risk: $100.0 million share repurchase program may increase stock-price volatility
  • Program discretion: repurchases may be suspended or terminated anytime, with $90.1 million remaining November 16, 2026
  • Liquidity risk: repurchases could potentially reduce market liquidity for common stock
  • Valuation risk: stock price may decline below repurchase prices, reducing shareholder value

AI summary of the OMER 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Omeros reported financial results for the three and nine months ended September 30, 2026
  • Detailed financial figures and management commentary appear in Exhibit 99.1 accompanying the 8-K

Item EX-99.1: Item EX-99.1

  • YARTEMLEA Q3 gross revenue $41.8M, up 29.6% sequentially, with net revenue $35.9M, supporting commercial momentum
  • Positive operating cash flow $13.3M and cash plus short-term investments $95.3M, improving near-term funding capacity
Filed Oct 30, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • CEO Gregory Demopulos granted performance option for 500,000 shares, signaling retention focus and substantial potential dilution
  • Exercise price $17.88, with four stock-price hurdles from $25.00 to $40.00 over a five-year performance period
Filed Aug 13, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded to nine directors with Joseph Schocken appointed effective August 12, 2026
  • Schocken joins the Audit Committee, adding investment banking and public-company governance experience

AI summaries of OMER 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OMER

Don't miss the next OMER filing

  • Alerts as it files. A push when OMER files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OMER, by share count.
  • Ask anything. An AI agent that reads every OMER filing and answers with sources.

OMER alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Demopulos Gregory A MDAOct 28, 2026-
Borges David J.MSep 23, 2026-
Borges David J.SellSep 23, 2026$20.95
Borges David J.MSep 23, 2026$15.58
Borges David J.SellSep 22, 2026$20.95
Borges David J.MSep 22, 2026$2.94
Borges David J.MSep 22, 2026-
Borges David J.MSep 22, 2026$3.93

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$164.5M-$169.3M-$122.8M
Net Income-$117.8M-$156.8M-$3.4M
Balance Sheet
Total Assets$378.3M$277.1M$325.6M
Equity-$25.0M-$182.6M-$121.2M
ROE471.6%85.9%2.8%
Per Share
EPS-$-2.70$-0.05
Cash Flow
Operating CF$74.7M-$148.8M-$116.1M
CapEx$426K$165K$65K

Source: XBRL data in OMEROS CORP (OMER)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate OMER share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OMER shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$324.9M
Q2 202625$155.1M
Q1 202628$151.1M
Q4 202524$267.7M
Q3 202524$70.3M
Q2 202525$44.7M
Q1 202523$77.9M
Q4 202419$76.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 195 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OMER filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
10-QNov 16, 2026Analysis
4Oct 30, 2026--
8-KOct 30, 2026Analysis-
4Sep 24, 2026--
4Sep 1, 2026--
4Aug 28, 2026--
4Aug 25, 2026--
4Aug 21, 2026--
4Aug 18, 2026--
4Aug 17, 2026--
8-KAug 13, 2026Analysis-
8-KAug 12, 2026Analysis-
10-QAug 12, 2026Analysis
4Jul 24, 2026--
4Jul 24, 2026--
4Jul 24, 2026--
8-KJul 20, 2026Analysis-
8-KJul 6, 2026Analysis-
8-KJun 25, 2026Analysis-
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 22, 2026--

Related Health Care companies

All Health Care →

OMER SEC filings: frequently asked questions

Are OMER insiders buying or selling?

In the last 90 days, OMEROS CORP (OMER) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $1.6 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold OMER stock?

As of September 30, 2026, the largest OMEROS CORP (OMER) holders among the 13F filers tracked by SignalX were BlackRock ($115.1 million), Vanguard Capital Management LLC ($58.2 million), State Street Corp ($42.7 million), Vanguard Portfolio Management LLC ($18.4 million), Morgan Stanley ($15.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did OMER report in its latest 8-K?

OMEROS CORP (OMER) filed an 8-K on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Omeros reported financial results for the three and nine months ended September 30, 2026.

What are the latest OMER SEC filings?

OMEROS CORP (OMER) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on October 30, 2026.

What is OMER's SEC CIK number?

OMEROS CORP (OMER)'s SEC Central Index Key (CIK) is 1285819. EDGAR lists every OMER filing under that number.

Ask anything about OMER

The research agent reads OMER's filings, financials, insider trades and 13F holders, then answers with sources.